SG Americas Securities LLC Grows Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

SG Americas Securities LLC boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 4,857.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 567,653 shares of the biotechnology company’s stock after buying an additional 556,202 shares during the period. SG Americas Securities LLC owned approximately 0.20% of Exelixis worth $20,958,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Coppell Advisory Solutions LLC bought a new position in Exelixis in the 4th quarter valued at $25,000. Colonial Trust Co SC boosted its holdings in Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 765 shares during the period. Principal Securities Inc. boosted its holdings in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 373 shares during the period. Kestra Investment Management LLC bought a new position in Exelixis in the 4th quarter valued at $39,000. Finally, Crowley Wealth Management Inc. bought a new position in Exelixis in the 4th quarter valued at $50,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Exelixis news, EVP Patrick J. Haley sold 126,383 shares of the business’s stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $47.96, for a total value of $6,061,328.68. Following the transaction, the executive vice president now owns 446,459 shares in the company, valued at approximately $21,412,173.64. The trade was a 22.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Dana Aftab sold 1,508 shares of the business’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $39.00, for a total transaction of $58,812.00. Following the completion of the transaction, the executive vice president now owns 693,181 shares in the company, valued at $27,034,059. The trade was a 0.22% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 458,113 shares of company stock worth $21,024,817 in the last 90 days. 2.82% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have commented on EXEL shares. Stifel Nicolaus raised their price target on shares of Exelixis from $36.00 to $38.00 and gave the company a “hold” rating in a report on Wednesday, May 14th. Bank of America raised their price target on shares of Exelixis from $45.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, June 5th. Wells Fargo & Company reaffirmed a “market outperform” rating on shares of Exelixis in a report on Thursday, April 17th. Wall Street Zen downgraded shares of Exelixis from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 15th. Finally, Piper Sandler lifted their price objective on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $39.35.

Exelixis Stock Down 0.9%

Shares of NASDAQ:EXEL opened at $42.52 on Wednesday. The stock has a market cap of $11.60 billion, a PE ratio of 24.02, a PEG ratio of 1.13 and a beta of 0.28. The company’s fifty day moving average is $39.27 and its 200 day moving average is $36.76. Exelixis, Inc. has a 52 week low of $21.36 and a 52 week high of $48.85.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.